Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003783 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00003783 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 36 participants.
The verdict
NCT00003783, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and combining drugs in different ways may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating children who have very high risk acute lymphocytic leukemia.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1999-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003783
The ClinicalTrials.gov registry entry for NCT00003783 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003783 about?
NCT00003783 is a clinical study titled "Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and combining drugs in different ways may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating chil...
What is the current status of trial NCT00003783?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 1999-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00003783?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003783?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.